Summit Therapeutics (SMMT) Price & Analysis

Compare

1,630 Followers

SMMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.76 - $36.91

Previous CloseN/A

Volume1.23M

Average Volume (3M)2.87M

Market Cap

$17.61B

Enterprise Value$15.51B

Total Cash (Recent Filing)$297.87M

Total Debt (Recent Filing)$5.55M

Price to Earnings (P/E)―

Beta2.36

Next Earnings

Nov 05, 2025

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding742,846,700

10 Day Avg. Volume3,199,264

30 Day Avg. Volume2,869,691

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.03K

Enterprise Value/Ebitda-20.87

Forecast

1Y Price Target

$31.67

Price Target Upside33.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Approval And PerceptionThe confirmed OS win in China now re-rates confidence, shifts perception, and sets a higher share price floor.

Efficacy And Competitive EdgeIvonescimab's performance in the HARMONi-2 trial was the first to show superiority over a leading competitor in 1L NSCLC, suggesting a strong competitive advantage.

Market PotentialIvonescimab's engagement of PD-1 and VEGF has shown superiority over chemotherapy and other treatments, paving the way to capture a significant portion of the ~$50B checkpoint inhibitor market.

Bears Say

Financial SustainabilitySummit ended the quarter with $297.9 M in cash and cash equivalents and remains in a position where funds are insufficient to sustain operations beyond 3Q26.

Funding And Partnership NeedsSummit lacks the means to rapidly advance ivonescimab in combination regimens without a partnership.

Market RisksReiterate UP rating and see downside potential from HARMONi.

Summit Therapeutics News

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4d ago

IBIO

OCEA

Summit Therapeutics falls -9.4%

Summit Therapeutics (SMMT) is down -9.4%, or -$2.52 to $24.45. Published first on TheFly – the ultimate source...

6d ago

SMMT

Summit Therapeutics falls -6.9%

Summit Therapeutics (SMMT) is down -6.9%, or -$1.86 to $25.12. Published first on TheFly – the ultimate source...

6d ago

SMMT

Akeso says ivonescimab met overall survival endpoint in final anlysis

Akeso (AKESF) announced in its first half results yesterday that ivonescimab met the overall survival endpoint in the...

6d ago

SMMT

Summit Therapeutics price target raised to $50 from $44 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Summit Therapeutics (SMMT) to $50 from $44 and keeps a...

6d ago

SMMT

Summit Therapeutics put volume heavy and directionally bearish

Bearish flow noted in Summit Therapeutics (SMMT) with 1,584 puts trading, or 2x expected. Most active are 9/5...

11d ago

SMMT

Summit Therapeutics put volume heavy and directionally bearish

Bearish flow noted in Summit Therapeutics (SMMT) with 1,231 puts trading, or 1.6x expected. Most active are Oct-25...

14d ago

SMMT

Piper starts Summit Therapeutics with Neutral on high expectations

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics (SMMT) with a Neutral rating and...

14d ago

SMMT

Summit Therapeutics initiated with a Neutral at Piper Sandler

Piper Sandler initiated coverage of Summit Therapeutics (SMMT) with a Neutral rating and $21 price target Published first...

14d ago

SMMT

Summit going concern language ‘non-issue,’ says Citi

Citi views the going concern language in Summit Therapeutics (SMMT)’ quarterly filing as a “non-issue.” The company can...

20d ago

SMMT

Summit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Summit Therapeutics today and set a price target...

6d ago

SMMT

Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on SMMT stock, giving a Buy rating...

20d ago

SMMT

Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments

Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics today and set a price target of...

20d ago

SMMT

Ivonescimab’s Promising Potential to Outperform KEYTRUDA: A Strong Buy Recommendation

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Summit Therapeutics, with...

21d ago

SMMT

SMMT FAQ

What was Summit Therapeutics’s price range in the past 12 months?

Summit Therapeutics lowest stock price was $11.76 and its highest was $36.91 in the past 12 months.

What is Summit Therapeutics’s market cap?

Summit Therapeutics’s market cap is $17.61B.

When is Summit Therapeutics’s upcoming earnings report date?

Summit Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 64 days.

How were Summit Therapeutics’s earnings last quarter?

Summit Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.669.

Is Summit Therapeutics overvalued?

According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Summit Therapeutics pay dividends?

Summit Therapeutics does not currently pay dividends.

What is Summit Therapeutics’s EPS estimate?

Summit Therapeutics’s EPS estimate is -0.18.

How many shares outstanding does Summit Therapeutics have?

Summit Therapeutics has 742,846,700 shares outstanding.

What happened to Summit Therapeutics’s price movement after its last earnings report?

Summit Therapeutics reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went down -9.097%.

Which hedge fund is a major shareholder of Summit Therapeutics?

Currently, no hedge funds are holding shares in SMMT

Summit Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-328.30%

Trailing 12-Months

Asset Growth

-5.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Summit Therapeutics

Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibiotics to combat infections caused by multi-drug resistant bacteria. The company operates in the healthcare sector, with a primary focus on developing new treatments for infectious diseases through its innovative pipeline of antibiotic candidates.

Summit Therapeutics (SMMT) Earnings & Revenues

Historic Earnings Reports

SMMT Company Deck

SMMT Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several significant achievements, particularly the approval of ivonescimab in China and successful clinical trial results, indicating a promising outlook for Summit Therapeutics. Despite some concerns over increased operating expenses and uncertainty in OS benefit, the sentiment remains largely optimistic.View all SMMT earnings summaries

SMMT Stock 12 Month Forecast

Average Price Target

$31.67

▲(33.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","30":"$30","51":"$51","19.5":"$19.5","40.5":"$40.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19.5,30,40.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,28.833846153846153,30.59769230769231,32.36153846153846,34.12538461538462,35.88923076923077,37.653076923076924,39.41692307692308,41.18076923076923,42.94461538461539,44.708461538461535,46.472307692307695,48.23615384615385,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,27.423846153846153,27.77769230769231,28.13153846153846,28.485384615384618,28.83923076923077,29.193076923076923,29.54692307692308,29.90076923076923,30.254615384615384,30.60846153846154,30.962307692307693,31.31615384615385,{"y":31.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.07,25.91076923076923,24.751538461538463,23.592307692307692,22.433076923076925,21.273846153846154,20.114615384615384,18.955384615384617,17.796153846153846,16.636923076923075,15.477692307692308,14.318461538461538,13.159230769230769,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >